肌肉量影响紫杉醇全身暴露并可能指导个体化给药
最优模型为二室模型,T11骨骼肌面积为紫杉醇分布容积的协变量;模拟提示对骨骼肌面积4907-7080 mm2和<4907 mm2的患者分别将输注时间从1小时延长至2小时和3小时,可将Cmax>2885 ng/mL的风险限制在<50%以下,从而减少周围神经病变并仅轻微增加总体全身暴露。
要点
- T11骨骼肌面积是紫杉醇分布容积的独立协变量。
- 骨骼肌面积<4907 mm2者延长输注至3小时可降低Cmax超标风险。
- 骨骼肌面积4907-7080 mm2者延长至2小时可降低神经病变风险。
核心结论
- 对约25%低骨骼肌面积患者延长紫杉醇输注时间,预测可减少周围神经病变并维持全身暴露,提示基于身体成分的个体化给药可能改善治疗结局。
研究设计与样本
- 于首次输注结束时测定紫杉醇浓度以估算Cmax,并使用CT扫描测量29项身体成分特征纳入药代动力学建模。
- 采用蒙特卡洛模拟确定限制Cmax>2885 ng/mL概率的输注时长,该阈值基于既往研究与不可接受的周围神经病变风险相关。
主要发现
- 最优模型为二室药代动力学模型,以T11骨骼肌面积作为紫杉醇分布容积(Vd)的协变量。
- 模拟提示,对骨骼肌面积4907-7080 mm2的患者将标准紫杉醇剂量输注时间从1小时延长至2小时,可将Cmax>2885 ng/mL的风险限制在<50%。
- 对骨骼肌面积<4907 mm2的患者将输注时间延长至3小时,同样可将Cmax>2885 ng/mL的风险限制在<50%,从而减少神经病变,同时仅轻微增加总体全身紫杉醇暴露。
临床怎么用
- 可考虑利用CT测量的T11骨骼肌面积识别低肌肉量乳腺癌患者,这类患者接受每周80 mg/m2紫杉醇时周围神经病变风险较高。
- 对骨骼肌面积4907-7080 mm2和<4907 mm2的患者,可分别考虑将紫杉醇输注时间从1小时延长至2小时和3小时,以降低Cmax>2885 ng/mL的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Patients with low muscle mass have increased risk of paclitaxel-induced peripheral neuropathy, which is dependent on systemic paclitaxel exposure. Dose optimization may be feasible through the secondary use of radiologic data for body composition. The objective of this study was to interrogate morphomic parameters as predictors of paclitaxel pharmacokinetics to identify alternative dosing strategies that may improve treatment outcomes. METHODS: This was a secondary analysis of female patients with breast cancer scheduled to receive 80 mg/m2 weekly paclitaxel infusions. Paclitaxel was measured at the end of initial infusion to estimate maximum concentration (Cmax ). Computed tomography (CT) scans were used to measure 29 body composition features for inclusion in pharmacokinetic modelling. Monte Carlo simulations were performed to identify infusion durations that limit the probability of exceeding Cmax > 2885 ng/mL, which was selected based on prior work linking this to an unacceptable risk of peripheral neuropathy. RESULTS: Thirty-nine patients were included in the analysis. The optimal model was a two-compartment pharmacokinetic model with T11 skeletal muscle area as a covariate of paclitaxel volume of distribution (Vd). Simulations suggest that extending infusion of the standard paclitaxel dose from 1 hour to 2 and 3 hours in patients who have skeletal muscle area 4907-7080 mm2 and <4907 mm2 , respectively, would limit risk of Cmax > 2885 ng/mL to <50%, consequently reducing neuropathy, while marginally increasing overall systemic paclitaxel exposure. CONCLUSION: Extending paclitaxel infusion duration in ~25% of patients who have low skeletal muscle area is predicted to reduce peripheral neuropathy while maintaining systemic exposure, suggesting that personalizing paclitaxel dosing based on body composition may improve treatment outcomes.
引用
- Hertz DL, Chen L, Henry NL, et al. Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing. Br J Clin Pharmacol. 2022. PMID: 35083783. doi:10.1111/bcp.15244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。